Date of Award
M.S. in Pharmaceutical Science
Pharmaceutics and Drug Delivery
Michael A. Repka
Natamycin (NT) is a commercially available antifungal drug used for the treatment of fungal keratitis, an infection which affects the clear corneal surface and its associated layers. Currently, NT is available commercially as a 5% w/v ophthalmic suspension, to be administered topically. The main objective of the present investigation was to develop and evaluate the natamycin loaded nanosuspension (NT-NS), as well as it’s corresponding in-situ gel (NT-NS-GG), for the treatment of fungal keratitis. NT-NS was prepared using homogenization technique and optimized based on size, PDI, zeta potential (ZP), assay and process stability. Further, optimized NT-NS was modified into an in-situ gel with the addition of 0.2% gellan gum as a gelling agent and evaluated for rheological properties. in vitro release and trans corneal permeation studies were performed. Differential scanning calorimetry studies shono interaction between the drug and other excipients being formulated into a NS. Particle size, PDI, ZP and assay of the optimized NT-NS formulation (formulation LP1) were 586. ± 61.3, 0.447 ± 0.12, -38.97 and 107 ± 0.6%, respectively. LP1 formulation was stable for up to 4 weeks under refrigerated and at room temperature conditions. in-situ gels shosatisfactory rheological properties, prolonged drug release and permeation through rabbit corneas. The results suggest that NT loaded NS could be an alternative topical ocular dosage form.
Joshi, Poorva H., "Nanosuspension Based Electrolyte Sensitive In Situ Gel for Topical Ocular Delivery of Natamycin" (2019). Electronic Theses and Dissertations. 1624.